Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Wednesday

Anavex Life Sciences (NASDAQ:AVXL) will likely be announcing its Q1 2026 results before the market opens on Wednesday, February 11th. Analysts expect Anavex Life Sciences to post earnings of ($0.10) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, February 9, 2026 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. During the same period in the prior year, the business posted ($0.14) EPS. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Down 2.9%

Anavex Life Sciences stock opened at $4.39 on Wednesday. The stock has a market cap of $392.25 million, a price-to-earnings ratio of -8.13 and a beta of 1.21. The business has a 50-day simple moving average of $4.27 and a 200 day simple moving average of $7.25. Anavex Life Sciences has a 52 week low of $2.86 and a 52 week high of $13.99.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Anavex Life Sciences in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Jones Trading cut shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $22.00.

Institutional Trading of Anavex Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming purchased a new stake in shares of Anavex Life Sciences during the second quarter valued at approximately $26,000. Quarry LP bought a new stake in Anavex Life Sciences during the 3rd quarter valued at $36,000. Russell Investments Group Ltd. boosted its position in Anavex Life Sciences by 11,540.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 6,924 shares during the period. Prudential Financial Inc. bought a new stake in Anavex Life Sciences in the 2nd quarter worth $95,000. Finally, Sei Investments Co. purchased a new position in shares of Anavex Life Sciences in the second quarter valued at about $107,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.